Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-naïve HIV-1-infected adult subjects.

@article{Carosi2009StudyOO,
  title={Study of once-daily versus twice-daily fosamprenavir plus ritonavir administered with abacavir/lamivudine once daily in antiretroviral-na{\"i}ve HIV-1-infected adult subjects.},
  author={Carosi and Lazzarin and Stellbrink and Moyle and Rugina and Staszewski and Givens and Jw Ross and Granier and Ait-Khaled and Leather and Nichols},
  journal={HIV clinical trials},
  year={2009},
  volume={10 6},
  pages={
          356-67
        }
}
PURPOSE Fosamprenavir/ritonavir 1400 mg/100 mg once-daily regimen may have a more favourable tolerability and lipid profile than the fosamprenavir/ritonavir twice-daily regimen, while maintaining comparable antiviral efficacy. METHODS This open-label study had a group-sequential design with a stage 1 Week 24 futility analysis, with both efficacy and safety go-criteria for progression to stage 2. There were 214 antiretroviral-naive, HIV-1-infected subjects who were randomised to receive either… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-2 of 2 citations